Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arterra Bioscience SpA ( (IT:ARBS) ) has provided an update.
Arterra Bioscience S.p.A. has secured funding for its ‘SmartLAB 2.0’ project, valued at approximately €3 million, aimed at developing an innovative platform using lactic bacteria for industrial production in cosmetics, nutraceuticals, agriculture, and agri-food sectors. The project, which will last two years, underscores Arterra’s commitment to sustainable biotechnological solutions, enhancing innovation, employment, and competitiveness in the Campania region.
More about Arterra Bioscience SpA
Arterra Bioscience S.p.A. is an Italian green biotech company specializing in research and development in biotechnology. Listed on the Euronext Growth Milan market since 2019, the company was founded in 2004 by CEO Gabriella Colucci. Arterra focuses on developing enabling technologies using living organisms for applications in cosmetics, agriculture, and nutraceuticals. The company is known for its collaborations with various companies and research institutes, including a joint venture with Intercos S.p.A. for innovative skincare products.
Average Trading Volume: 12,138
Technical Sentiment Signal: Buy
Current Market Cap: €14.92M
Learn more about ARBS stock on TipRanks’ Stock Analysis page.